Wellstar Partners with BD to Enhance Medication Management Safety
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Source: PRnewswire
- Strategic Partnership: Wellstar Health System has formed a strategic partnership with BD to enhance the safety and quality of medication delivery by integrating BD Pyxis™ Pro and BD Alaris™ platforms, aiming to provide safer and more consistent care for patients.
- Technology Upgrade: The new system leverages artificial intelligence to provide enterprise-wide visibility into medication inventory, with real-time insights and customizable dashboards that help clinicians identify trends, ensuring medication availability, reducing waste, and optimizing labor efficiency.
- Clinical Efficiency Boost: With barcode scanning, Wellstar clinicians can send infusion orders directly from the electronic medical record and receive infusion statuses back into the EMR, streamlining workflows and allowing clinicians to focus more on patient care.
- Industry Leadership: This collaboration not only enhances Wellstar's technological capabilities in medication management but also drives future innovations through participation in BD's Strategic Development Council, addressing real-world challenges faced by large, complex healthcare systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to rise
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 146.950
Low
157.00
Averages
192.64
High
232.00
Current: 146.950
Low
157.00
Averages
192.64
High
232.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BD Launches New Laser System to Enhance Urology Efficiency
- Technological Innovation: BD has launched the Elyra™ Thulium Fiber Laser System, designed to enhance efficiency and versatility for urology teams in kidney stone management and soft tissue procedures, significantly improving clinical operations by supporting efficient stone dusting and reducing stone migration.
- User Experience Enhancement: The system features an intuitive user interface, customizable presets, quick startup capabilities, and an optional wireless footswitch, which help streamline workflows in stone lithotripsy and soft tissue procedures, thereby boosting clinicians' confidence during operations.
- Positive Clinical Feedback: BD recently completed its first clinical cases using the Elyra™ Plus TFL System at a leading medical center, receiving positive feedback from urologists and laser technicians who appreciated the system's safety features and ease of use.
- Market Expansion: The Elyra™ and Elyra™ Plus TFL Systems are now available in the United States, as BD continues to expand its urologic stone management portfolio by integrating comprehensive solutions that support providers in optimizing performance and preparing for the future of urologic care.
See More
BD Appoints New Executive Vice President
- Leadership Change: BD has announced the appointment of Peter Menziuso as Executive Vice President and President of BD Interventional effective June 1, aiming to leverage his over 30 years of global healthcare leadership experience to drive sustained growth.
- Performance-Driven Background: Menziuso previously served as Company Group Chairman at Johnson & Johnson Vision, overseeing a $5 billion global business across commercial operations, R&D, and supply chain, showcasing his exceptional ability to drive performance.
- Strategic Leadership Advantage: With a customer-centric approach, Menziuso excels in building high-performing teams and translating strategy into sustained performance, which is expected to bring new growth momentum to BD Interventional and further solidify its market leadership.
- Company Vision and Mission: As one of the world's largest pure-play medical technology companies, BD is committed to advancing healthcare through innovation, and Menziuso's addition is anticipated to enhance clinical operations and improve patient care quality, strengthening the company's influence in the global healthcare market.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Becton Dickinson Exceeds Q2 Estimates with $4.71B Revenue
- Performance Beat: Becton Dickinson reported Q2 revenue of $4.71 billion, surpassing market expectations, indicating strong demand and solid market share in the medical device sector.
- Earnings Outlook Raised: The company raised its 2026 earnings outlook, reflecting confidence in future growth, which is expected to further boost investor confidence and stock performance.
- Executive Change: The appointment of new CFO Vitor Roque signifies a major shift in financial management and strategic execution, potentially impacting future financial decisions and investment directions.
- Positive Market Reaction: Following the earnings beat and raised outlook, the market reacted positively to Becton Dickinson, likely attracting more investor attention and enhancing the company's competitiveness in the healthcare industry.
See More
Becton, Dickinson Reports Strong Q2 2026 Earnings with Adjusted EPS Guidance Increase
- Revenue Growth: Becton, Dickinson reported Q2 revenue of $4.7 billion, a 2.6% increase, with double-digit growth in biologic drug delivery and Advanced Patient Monitoring, indicating strong performance in the medical device market.
- Adjusted EPS Increase: The company achieved an adjusted EPS of $2.90, up 3.9%, and raised its full-year adjusted EPS guidance to $12.52 to $12.72, reflecting management's confidence in future performance.
- Cash Flow and Shareholder Returns: Year-to-date free cash flow reached $1.1 billion, with approximately $2.3 billion returned to shareholders, including $2 billion in share repurchases and $0.3 billion in dividends, showcasing strong capital allocation capabilities.
- FDA Warning Impact: Following an FDA warning for the El Paso facility, the company voluntarily placed ChloraPrep and PurPrep on ship hold, expecting testing to take about three weeks; however, management emphasized no patient safety signals, demonstrating robust risk management.
See More
Becton, Dickinson Reports Strong Q2 Results, Raises Full-Year Earnings Outlook
- Significant Revenue Growth: Becton, Dickinson reported Q2 revenue of $4.7 billion, reflecting approximately 5% year-over-year growth, exceeding market expectations by $30 million, driven by $1.6 billion and $1.1 billion contributions from Medical Essentials and Connected Care segments, respectively, indicating strong performance in the healthcare sector.
- Strong U.S. Market Performance: U.S. sales climbed approximately 5% year-over-year on a forex-adjusted basis to $2.9 billion, successfully offsetting headwinds in overseas markets, particularly with a ~1% year-over-year decline in sales from the Medical Essentials unit, showcasing the company's competitive edge domestically.
- Upward Earnings Guidance: The company reported adjusted earnings of $2.90 per diluted share, beating consensus estimates by $0.13, while raising its FY 2026 adjusted EPS outlook to $12.52-$12.72, reflecting confidence in future growth.
- Executive Appointment: Becton, Dickinson announced the permanent appointment of Vitor Roque as CFO effective May 7, having served as interim CFO since December, indicating a strategic decision for stability within the executive team.
See More
BD Launches New Laser System to Enhance Urology Efficiency
- Technological Innovation: BD has launched the Elyra™ Thulium Fiber Laser System, designed to enhance efficiency and versatility for urology teams in kidney stone management and soft tissue procedures, significantly improving clinical operations by supporting efficient stone dusting and reducing stone migration.
- User Experience Enhancement: The system features an intuitive user interface, customizable presets, quick startup capabilities, and an optional wireless footswitch, which help streamline workflows in stone lithotripsy and soft tissue procedures, thereby boosting clinicians' confidence during operations.
- Positive Clinical Feedback: BD recently completed its first clinical cases using the Elyra™ Plus TFL System at a leading medical center, receiving positive feedback from urologists and laser technicians who appreciated the system's safety features and ease of use.
- Market Expansion: The Elyra™ and Elyra™ Plus TFL Systems are now available in the United States, as BD continues to expand its urologic stone management portfolio by integrating comprehensive solutions that support providers in optimizing performance and preparing for the future of urologic care.
See More
BD Appoints New Executive Vice President
- Leadership Change: BD has announced the appointment of Peter Menziuso as Executive Vice President and President of BD Interventional effective June 1, aiming to leverage his over 30 years of global healthcare leadership experience to drive sustained growth.
- Performance-Driven Background: Menziuso previously served as Company Group Chairman at Johnson & Johnson Vision, overseeing a $5 billion global business across commercial operations, R&D, and supply chain, showcasing his exceptional ability to drive performance.
- Strategic Leadership Advantage: With a customer-centric approach, Menziuso excels in building high-performing teams and translating strategy into sustained performance, which is expected to bring new growth momentum to BD Interventional and further solidify its market leadership.
- Company Vision and Mission: As one of the world's largest pure-play medical technology companies, BD is committed to advancing healthcare through innovation, and Menziuso's addition is anticipated to enhance clinical operations and improve patient care quality, strengthening the company's influence in the global healthcare market.
See More
Roundhill Memory ETF DRAM Attracts Over $5 Billion in Investments
- Memory Supercycle: The Roundhill Memory ETF (DRAM) attracted over $5 billion in investments within a month, including $1.1 billion on Thursday alone, indicating strong market demand for memory stocks driven by surging AI computing needs.
- Core Holdings Performance: The ETF's core holdings feature leading memory manufacturers like SK Hynix, Micron, and Samsung, allowing investors to gain broad exposure to these high-growth companies, including those not listed on U.S. exchanges.
- Market Reaction: Micron's stock surged over 200 points in a week, climbing from $542 to $747, reflecting optimistic market expectations for memory product demand, with a price-to-earnings ratio of only 9 times projected earnings for the next 12 months, highlighting its appeal as a quality stock.
- Investment Opportunities: Despite waning interest in data center stocks, investors can still capitalize on potential gains in the memory and cooling sectors by purchasing instruments like the DRAM ETF, especially as major tech companies continue to invest heavily in data centers.
See More
Becton Dickinson Exceeds Q2 Estimates with $4.71B Revenue
- Performance Beat: Becton Dickinson reported Q2 revenue of $4.71 billion, surpassing market expectations, indicating strong demand and solid market share in the medical device sector.
- Earnings Outlook Raised: The company raised its 2026 earnings outlook, reflecting confidence in future growth, which is expected to further boost investor confidence and stock performance.
- Executive Change: The appointment of new CFO Vitor Roque signifies a major shift in financial management and strategic execution, potentially impacting future financial decisions and investment directions.
- Positive Market Reaction: Following the earnings beat and raised outlook, the market reacted positively to Becton Dickinson, likely attracting more investor attention and enhancing the company's competitiveness in the healthcare industry.
See More
Becton, Dickinson Reports Strong Q2 2026 Earnings with Adjusted EPS Guidance Increase
- Revenue Growth: Becton, Dickinson reported Q2 revenue of $4.7 billion, a 2.6% increase, with double-digit growth in biologic drug delivery and Advanced Patient Monitoring, indicating strong performance in the medical device market.
- Adjusted EPS Increase: The company achieved an adjusted EPS of $2.90, up 3.9%, and raised its full-year adjusted EPS guidance to $12.52 to $12.72, reflecting management's confidence in future performance.
- Cash Flow and Shareholder Returns: Year-to-date free cash flow reached $1.1 billion, with approximately $2.3 billion returned to shareholders, including $2 billion in share repurchases and $0.3 billion in dividends, showcasing strong capital allocation capabilities.
- FDA Warning Impact: Following an FDA warning for the El Paso facility, the company voluntarily placed ChloraPrep and PurPrep on ship hold, expecting testing to take about three weeks; however, management emphasized no patient safety signals, demonstrating robust risk management.
See More
Becton, Dickinson Reports Strong Q2 Results, Raises Full-Year Earnings Outlook
- Significant Revenue Growth: Becton, Dickinson reported Q2 revenue of $4.7 billion, reflecting approximately 5% year-over-year growth, exceeding market expectations by $30 million, driven by $1.6 billion and $1.1 billion contributions from Medical Essentials and Connected Care segments, respectively, indicating strong performance in the healthcare sector.
- Strong U.S. Market Performance: U.S. sales climbed approximately 5% year-over-year on a forex-adjusted basis to $2.9 billion, successfully offsetting headwinds in overseas markets, particularly with a ~1% year-over-year decline in sales from the Medical Essentials unit, showcasing the company's competitive edge domestically.
- Upward Earnings Guidance: The company reported adjusted earnings of $2.90 per diluted share, beating consensus estimates by $0.13, while raising its FY 2026 adjusted EPS outlook to $12.52-$12.72, reflecting confidence in future growth.
- Executive Appointment: Becton, Dickinson announced the permanent appointment of Vitor Roque as CFO effective May 7, having served as interim CFO since December, indicating a strategic decision for stability within the executive team.
See More
